search
Back to results

Phase 4 Study in the Elderly Patients With T2DM (GLYCEMIA)

Primary Purpose

Type 2 Diabetes Mellitus, Elderly

Status
Completed
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
Vildagliptin
"Usual Care"
Sponsored by
Novartis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Diabetes mellitus, vildagliptin, hypoglycemia, elderly

Eligibility Criteria

65 Years - 80 Years (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 2 Diabetes Mellitus (DM) patients aged 65 to 80 years, willing to perform SMBG in case of symptomatic hypoglycemia.
  • HbA1c: 6.5 to 8.5 % with max tolerated dose of metformin monotherapy for at least 3 months.

Exclusion Criteria:

  • Age > 80 yrs
  • BMI < 22 and ≥ 45 kg/m2
  • Secondary T2 DM
  • Hepatic failure, moderate/severe renal failure (Cl < 50 ml/min) and CHF III & IV
  • ASAT / ALAT > 3 ULN, creatinine clearance < 50 ml/min Other protocol-defined inclusion/exclusion criteria may apply

Sites / Locations

  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site #2
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site #2
  • Novartis Investigative Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Vildagliptin

other Oral Antidiabetic Drug in a different therapeutic class

Arm Description

Outcomes

Primary Outcome Measures

Percent of patients in each of the two treatment groups presenting no hypoglycemia (confirmed events with SMBG and severe episodes) after 24 wk of randomized therapy added to their ongoing metformin background therapy.

Secondary Outcome Measures

Percent of patients reaching their therapeutic goal
Percent of patients with success of primary EP (no confirmed/severe hypoglycemia) and reaching their therapeutic goal
Glycemic control assessed by A1C, and the mean of 6 Points self-monitoring of blood glucose (SMBG) at baseline and after 24 weeks.

Full Information

First Posted
November 9, 2010
Last Updated
February 21, 2017
Sponsor
Novartis
search

1. Study Identification

Unique Protocol Identification Number
NCT01238978
Brief Title
Phase 4 Study in the Elderly Patients With T2DM
Acronym
GLYCEMIA
Official Title
A Multicenter, Prospective, Randomized, Open-label, Parallel Group Study to Investigate the Clinical Benefit on Hypoglycemia Frequency of 24 Weeks Treatment With Galvus Versus Usual Care (Any OAD of Another Class Added to Metformin Within SmPc) in Older Patients With Type 2 Diabetes Insufficiently Controlled by Metformin Monotherapy.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
October 2010 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
December 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis

4. Oversight

5. Study Description

Brief Summary
The study will assess the incidence of Hypoglycemia: Percent of patients presenting no hypoglycemia (confirmed events with SMBG and severe episodes) over 6 months follow up in T2DM patients treated with a DPP-4 inhibitor or another OAD as add-on therapy to metformin

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus, Elderly
Keywords
Diabetes mellitus, vildagliptin, hypoglycemia, elderly

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
46 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Vildagliptin
Arm Type
Experimental
Arm Title
other Oral Antidiabetic Drug in a different therapeutic class
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Vildagliptin
Intervention Type
Drug
Intervention Name(s)
"Usual Care"
Primary Outcome Measure Information:
Title
Percent of patients in each of the two treatment groups presenting no hypoglycemia (confirmed events with SMBG and severe episodes) after 24 wk of randomized therapy added to their ongoing metformin background therapy.
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Percent of patients reaching their therapeutic goal
Time Frame
24 weeks
Title
Percent of patients with success of primary EP (no confirmed/severe hypoglycemia) and reaching their therapeutic goal
Time Frame
24 weeks
Title
Glycemic control assessed by A1C, and the mean of 6 Points self-monitoring of blood glucose (SMBG) at baseline and after 24 weeks.
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 2 Diabetes Mellitus (DM) patients aged 65 to 80 years, willing to perform SMBG in case of symptomatic hypoglycemia. HbA1c: 6.5 to 8.5 % with max tolerated dose of metformin monotherapy for at least 3 months. Exclusion Criteria: Age > 80 yrs BMI < 22 and ≥ 45 kg/m2 Secondary T2 DM Hepatic failure, moderate/severe renal failure (Cl < 50 ml/min) and CHF III & IV ASAT / ALAT > 3 ULN, creatinine clearance < 50 ml/min Other protocol-defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigative Site
City
Armentieres
ZIP/Postal Code
59208
Country
France
Facility Name
Novartis Investigative Site
City
Brest
ZIP/Postal Code
29200
Country
France
Facility Name
Novartis Investigative Site
City
Caen
ZIP/Postal Code
14000
Country
France
Facility Name
Novartis Investigative Site
City
Creil
ZIP/Postal Code
60100
Country
France
Facility Name
Novartis Investigative Site #2
City
Paris
ZIP/Postal Code
75012
Country
France
Facility Name
Novartis Investigative Site
City
Paris
ZIP/Postal Code
75020
Country
France
Facility Name
Novartis Investigative Site
City
Pau
ZIP/Postal Code
64000
Country
France
Facility Name
Novartis Investigative Site
City
St Jean de la Ruelle
ZIP/Postal Code
45140
Country
France
Facility Name
Novartis Investigative Site
City
Strasbourg
ZIP/Postal Code
67000
Country
France
Facility Name
Novartis Investigative Site
City
Strasbourg
Country
France
Facility Name
Novartis Investigative Site
City
Toulouse
ZIP/Postal Code
31200
Country
France
Facility Name
Novartis Investigative Site
City
Tours
ZIP/Postal Code
37000
Country
France
Facility Name
Novartis Investigative Site
City
Venissieux
ZIP/Postal Code
69200
Country
France
Facility Name
Novartis Investigative Site #2
City
Venissieux
Country
France
Facility Name
Novartis Investigative Site
City
Versailles
ZIP/Postal Code
78000
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
22996038
Citation
Penfornis A, Bourdel-Marchasson I, Quere S, Dejager S. Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: the HYPOCRAS study. Diabetes Metab. 2012 Dec;38(6):550-7. doi: 10.1016/j.diabet.2012.08.003. Epub 2012 Sep 18.
Results Reference
result

Learn more about this trial

Phase 4 Study in the Elderly Patients With T2DM

We'll reach out to this number within 24 hrs